Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Novartis Animal Health UK Ltd
Address: Frimley Business Park
Frimley
Camberley
Surrey
GU16 7SR
Telephone: 01276 694402
Fax: 01276 694403
Presentation
Fawn coloured tablets marked with PLT on one side and double scored on the other. Each tablet contains:
Cinchophen
| 200 mg
| Prednisolone PhEur
| 1 mg
|
Uses
PLT Tablets are indicated for the treatment of osteoarthritis in the dog.
Dosage and administration
Recommended dosage is based on 25 mg cinchophen/kg bodyweight and 0.125 mg prednisolone/kg bodyweight. This equates to a dose of:
Dogs:
| 8 kg
| ½ tablet twice daily
|
| 16 kg
| 1 tablet twice daily
|
| 24 kg
| 1½ tablets twice daily
|
| 32 kg and over
| 2 tablets twice daily
|
The dose should be administered with food.
The length of treatment with PLT Tablets depends on the condition treated and the rapidity of response. If there is no improvement within the first 3 days, the dog should be re-examined by the veterinary surgeon. However, an initial treatment period should not exceed 14 days after which the dog's condition should be re-assessed by a veterinary surgeon and a 14 day treatment-free interval must be observed before continuing with further treatment. During a course of treatment the situation should be reviewed frequently by close veterinary supervision.
Owing to the prednisolone content, at the end of a treatment period, dose levels should be reduced gradually.
Contra-indications, warnings, etc
Not for use in any animal species other than the dog.
Not to be used in animals with the following conditions: Pregnancy, severe nephrosis, circulatory congestive conditions, hepatitis, previous adverse reaction to a steroid or NSAID treatment, concurrent diuretic therapy or treatment with other NSAIDs or steroids.
Systemic corticosteroid therapy is generally contra-indicated in patients with renal disease and diabetes mellitus. Should any treated animal show signs of vomiting, diarrhea, dullness or jaundice, or show no evidence of improvement after 3 days of treatment, discontinue therapy.
Anti-inflammatory corticosteroids, such as prednisolone, are known to exert a wide range of side-effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use and when esters possessing a long duration of action are administered. Dosage in medium to long term use should generally be kept to the minimum necessary to control symptoms.
Steroids themselves, during treatment, may cause Cushingoid symptoms involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, muscle weakness and wastage and osteoporosis may result. During therapy effective doses suppress the Hypothalamo-Pituitreal-Adrenal axis. Following cessation of treatment, symptoms of adrenal insufficiency extending to adrenocorticol atrophy can arise and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimising problems of adrenal insufficiency following the withdrawal of treatment, e.g. a gradual reduction of dosage (for further discussion see standard texts).
Systemically administered corticosteroids may cause polyuria, polydipsia and polyphagia, particularly during the early stages of therapy. Some corticosteroids may cause sodium and water retention and hypokalaemia in long term use. Systemic corticosteroids have caused deposition of calcium in the skin (calcinosis cutis).
Corticosteroids may delay wound healing and the immunosuppressant actions may weaken resistance to, or exacerbate existing infections. In the presence of bacterial infection, anti-bacterial drug cover is usually required when steroids are used. In the presence of viral infections, steroids may worsen or hasten the progress of the disease.
Gastro-intestinal ulceration has been reported in animals treated with corticosteroids and g.i.t. ulceration may be exacerbated by steroids in patients given non-steroidal anti-inflammatory drugs and in corticosteroid treated animals with spinal cord trauma. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Gastro-intestinal upsets have been reported. Should inappetance or vomiting occur, medication should be discontinued and the dog re-examined by a veterinary surgeon.
For animal treatment only.
Pharmaceutical precautions
Do not store above 25°C. Store in a dry place. Protect from light. Keep out of reach of children.
Disposal
Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Packaging Quantities
Containers of 1,000 tablets.
Further information Pharmacological Properties
Pharmacotherapeutic group: Corticosteroids for systemic use, combinations.
ATC Vet Code: QH02BX
Pharmacodynamic Properties
Prednisolone is a glucocorticoid, with widespread anti-inflammatory properties. Cinchophen is a non-steroidal anti-inflammatory drug thought to act principally by inhibition of the cyclooxygenase enzyme responsible for conversion of arachidonic acid into the inflammatory mediators prostaglandins.
Pharmacokinetic Particulars
No information supplied.
PHARMACEUTICAL PARTICULARS
List of Excipients:
Cellulose
Microcrystalline
Carmellose sodium (AcDiSol)
Povidone
Magnesium stearate
Calcium phosphate
Water de-ionised
Incompatibilities
Not applicable.
Shelf Life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years
Marketing authorisation number
Vm 12501/4127.
| 
